Literature DB >> 8918548

Topically applied human recombinant monoclonal IgG1 antibody and its Fab and F(ab')2 fragments protect mice from vaginal transmission of HSV-2.

L Zeitlin1, K J Whaley, P P Sanna, T R Moench, R Bastidas, A De Logu, R A Williamson, D R Burton, R A Cone.   

Abstract

A recombinant human anti-herpes simplex virus monoclonal IgG1, antibody and the corresponding Fab and F(ab')2 fragments were tested for efficacy in preventing vaginal transmission of HSV-2 infection in a well-established mouse model for genital herpes. IgG1, Fab, and F(ab')2 were approximately equally protective; vaginal delivery of 1-5 ng provided approximately 50% protection, and vaginal delivery of 400 ng completely protected mice from genital herpes infection (P < 0.001). These results suggest that topical applications of human monoclonal antibodies may be useful in developing new methods for preventing sexually transmitted disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8918548     DOI: 10.1006/viro.1996.0589

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  22 in total

Review 1.  Role of antibodies in controlling viral disease: lessons from experiments of nature and gene knockouts.

Authors:  P P Sanna; D R Burton
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Characterization of a type-common human recombinant monoclonal antibody to herpes simplex virus with high therapeutic potential.

Authors:  A De Logu; R A Williamson; R Rozenshteyn; F Ramiro-Ibañez; C D Simpson; D R Burton; P P Sanna
Journal:  J Clin Microbiol       Date:  1998-11       Impact factor: 5.948

3.  B Virus (Macacine herpesvirus 1) Glycoprotein D Is Functional but Dispensable for Virus Entry into Macaque and Human Skin Cells.

Authors:  Ludmila Perelygina; Irina Patrusheva; Mugdha Vasireddi; Nicole Brock; Julia Hilliard
Journal:  J Virol       Date:  2015-03-04       Impact factor: 5.103

4.  Ocular distribution, spectrum of activity, and in vivo viral neutralization of a fully humanized anti-herpes simplex virus IgG Fab fragment following topical application.

Authors:  Marianne Berdugo; Inna V Larsen; Claire Abadie; Catherine Deloche; Laura Kowalczuk; Elodie Touchard; Richard Dubielzig; Curtis R Brandt; Francine Behar-Cohen; Jean-Marc Combette
Journal:  Antimicrob Agents Chemother       Date:  2011-12-27       Impact factor: 5.191

5.  Neutralizing antibodies inhibit axonal spread of herpes simplex virus type 1 to epidermal cells in vitro.

Authors:  Z Mikloska; P P Sanna; A L Cunningham
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

6.  Localization of a passively transferred human recombinant monoclonal antibody to herpes simplex virus glycoprotein D to infected nerve fibers and sensory neurons in vivo.

Authors:  P P Sanna; T J Deerinck; M H Ellisman
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

7.  Virus-neutralizing activity mediated by the Fab fragment of a hemagglutinin-specific antibody is sufficient for the resolution of influenza virus infection in SCID mice.

Authors:  Krystyna Mozdzanowska; Jingqi Feng; Walter Gerhard
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

8.  Using Computational Modeling To Optimize the Design of Antibodies That Trap Viruses in Mucus.

Authors:  Timothy Wessler; Alex Chen; Scott A McKinley; Richard Cone; Gregory Forest; Samuel K Lai
Journal:  ACS Infect Dis       Date:  2015-10-17       Impact factor: 5.084

9.  Overcoming drug-resistant herpes simplex virus (HSV) infection by a humanized antibody.

Authors:  Adalbert Krawczyk; Michaela A E Arndt; Ludger Grosse-Hovest; Wilko Weichert; Bernd Giebel; Ulf Dittmer; Hartmut Hengel; Dirk Jäger; Karl E Schneweis; Anna M Eis-Hübinger; Michael Roggendorf; Jürgen Krauss
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-08       Impact factor: 11.205

Review 10.  Antibody-based concepts for multipurpose prevention technologies.

Authors:  Kevin J Whaley; Larry Zeitlin
Journal:  Antiviral Res       Date:  2013-11-01       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.